Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/30008
Title: Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.
Austin Authors: Goldinger, Simone M;Buder-Bakhaya, Kristina;Lo, Serigne N;Forschner, Andrea;McKean, Meredith;Zimmer, Lisa;Khoo, Chloe;Dummer, Reinhard;Eroglu, Zeynep;Buchbinder, Elizabeth I;Ascierto, Paolo A;Gutzmer, Ralf;Rozeman, Elisa A;Hoeller, Christoph;Johnson, Douglas B;Gesierich, Anja;Kölblinger, Peter;Bennannoune, Naima;Cohen, Justine V;Kähler, Katharina C;Wilson, Melissa A;Cebon, Jonathan S ;Atkinson, Victoria;Smith, Jessica L;Michielin, Olivier;Long, Georgina V;Hassel, Jessica C;Weide, Benjamin;Haydu, Lauren E;Schadendorf, Dirk;McArthur, Grant;Ott, Patrick A;Blank, Christian;Robert, Caroline;Sullivan, Ryan;Hauschild, Axel;Carlino, Matteo S;Garbe, Claus;Davies, Michael A;Menzies, Alexander M
Affiliation: University of Zurich, Department of Dermatology, Gloriastrasse 31 Zurich, 8091, Switzerland..
Melanoma Institute Australia, The University of Sydney, The Poche Centre, 40 Rocklands Road North Sydney NSW 2060, Australia..
University Hospital Heidelberg, Department of Dermatology and National Center for Cancer (NCT), Im Neuenheimer Feld 460 Heidelberg, 69120, Germany..
University of Tuebingen, Department of Dermatology, Liebermeisterstrasse 25, Tübingen, 72076, Germany..
University of Texas MD Anderson Cancer Center, Department of Melanoma Medical Oncology and Department of Surgical Oncology, 1400 Pressler Street, Houston, TX 77006 USA..
University Hospital Essen, Department of Dermatology, Essen & German Cancer Consortium, Partner Site Essen, Germany..
Peter MacCallum Cancer Centre, Melbourne, Australia..
Moffitt Cancer Center, Department of Cutaneous Oncology, 12902 Magnolia Drive, Tampa, FL 33612, USA..
Dana Farber Cancer Institute, 450 Brookline Ave., Boston, MA 02215, USA..
Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Napoli, Italy..
Skin Cancer Center, Department of Dermatology, Mühlenkreiskliniken, Ruhr University Bochum Campus Minden, Germany..
Antoni van Leeuwenhoek Hospital - The Netherlands Cancer Institute, Department of Medical Oncology and Immunology, Plesmanlaan 121 Amsterdam, 1066 CX, the Netherlands..
Medical University of Vienna, Department of Dermatology, Waehringer Guertel 18-20, Vienna, 1090, Austria..
Vanderbilt University Medical Center, Department of Medicine, Nashville, TN, USA..
University Hospital Wuerzburg, Department of Dermatology, Wuerzburg, Germany..
Department of Dermatology and Allergology, Paracelsus Medical University, Salzburg, Austria..
Gustave Roussy and Paris-Saclay University, 114 rue Edouard Vaillant Villejuif Cedex, 94805, France..
Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA..
Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Arnold-Heller-Strasse 3, Haus C, Kiel, 24105, Germany..
Perlmutter Cancer Center, NYU Langone Health, NYU School of Medicine, 160 E. 34th Street, New York, NY 10016, USA..
Olivia Newton-John Cancer Research Institute
University of QLD, Princess Alexandra Hospital, Greenslopes Private Hospital, 199 Ipswich Rd, Woolloongabba QLD 4102, Australia..
Crown Princess Mary Cancer Centre Westmead, Sydney, NSW, Australia..
Lausanne University Hospital, Department of Oncology, Precision Oncology Center, Rue du Bugnon 21, Lausanne, 1011, Switzerland..
Melanoma Institute Australia, The University of Sydney, The Poche Centre, 40 Rocklands Road North Sydney NSW 2060, Australia..
Royal North Shore Hospital, Reserve Road St Leonards NSW 2065, Australia..
Mater Hospital, 25 Rocklands Road, North Sydney NSW 2060, Australia..
Faculty of Medicine and Health, The University of Sydney, Sydney, Australia..
Charles Perkins Centre, The University of Sydney, Australia..
University Hospital Heidelberg, Department of Dermatology and National Center for Cancer (NCT), Im Neuenheimer Feld 460 Heidelberg, 69120, Germany..
University of Tuebingen, Department of Dermatology, Liebermeisterstrasse 25, Tübingen, 72076, Germany..
University of Texas MD Anderson Cancer Center, Department of Melanoma Medical Oncology and Department of Surgical Oncology, 1400 Pressler Street, Houston, TX 77006 USA..
University Hospital Essen, Department of Dermatology, Essen & German Cancer Consortium, Partner Site Essen, Germany..
Peter MacCallum Cancer Centre, Melbourne, Australia..
Dana Farber Cancer Institute, 450 Brookline Ave., Boston, MA 02215, USA..
Antoni van Leeuwenhoek Hospital - The Netherlands Cancer Institute, Department of Medical Oncology and Immunology, Plesmanlaan 121 Amsterdam, 1066 CX, the Netherlands..
Gustave Roussy and Paris-Saclay University, 114 rue Edouard Vaillant Villejuif Cedex, 94805, France..
Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA..
Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Arnold-Heller-Strasse 3, Haus C, Kiel, 24105, Germany..
Crown Princess Mary Cancer Centre Westmead, Sydney, NSW, Australia..
University of Tuebingen, Department of Dermatology, Liebermeisterstrasse 25, Tübingen, 72076, Germany..
University of Texas MD Anderson Cancer Center, Department of Melanoma Medical Oncology and Department of Surgical Oncology, 1400 Pressler Street, Houston, TX 77006 USA..
Issue Date: Feb-2022
metadata.dc.date: 2021
Publication information: European Journal of Cancer (Oxford, England : 1990) 2022; 162: 22-33
Abstract: Despite remarkably improved outcomes with immune checkpoint inhibition, many patients with metastatic melanoma will eventually require further therapy. Chemotherapy has limited activity when used first-line but can alter the tumour microenvironment and does improve efficacy when used in combination with immunotherapy in lung cancer. Whether chemotherapy after checkpoint inhibitor failure has relevant activity in patients with metastatic melanoma is unknown. Patients with metastatic melanoma treated with chemotherapy after progression on immunotherapy with checkpoint inhibitors were identified retrospectively from 24 melanoma centres. Objective response rate (ORR), progression-free survival (PFS), overall survival (OS) and safety were examined. In total, 463 patients were treated between 2007 and 2017. Fifty-six per cent had received PD-1-based therapy before chemotherapy. Chemotherapy regimens included carboplatin + paclitaxel (32%), dacarbazine (25%), temozolomide (15%), taxanes (9%, nab-paclitaxel 4%), fotemustine (6%) and others (13%). Median duration of therapy was 7.9 weeks (0-108). Responses included 0.4% complete response (CR), 12% partial response (PR), 21% stable disease (SD) and 67% progressive disease (PD). Median PFS was 2.6 months (2.2, 3.0), and median PFS in responders was 8.7 months (6.3, 16.3), respectively. Twelve-month PFS was 12% (95% CI 2-15%). In patients who had received anti-PD-1 before chemotherapy, the ORR was 11%, and median PFS was 2.5 months (2.1, 2.8). The highest activity was achieved with single-agent taxanes (N = 40), with ORR 25% and median PFS 3.9 months (2.1, 6.2). Median OS from chemotherapy start was 7.1 months (6.5, 8.0). Subsequent treatment with checkpoint inhibitors achieved a response rate of 16% with a median PFS of 19.1 months (2.0-43.1 months). No unexpected toxicities were observed. Chemotherapy has a low response rate and short PFS in patients with metastatic melanoma who have failed checkpoint inhibitor therapy, although activity varied between regimens. Chemotherapy has a limited role in the management of metastatic melanoma.
URI: https://ahro.austin.org.au/austinjspui/handle/1/30008
DOI: 10.1016/j.ejca.2021.11.022
ORCID: 0000-0002-3898-950X
Journal: European Journal of Cancer (Oxford, England : 1990)
PubMed URL: 34952480
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/34952480/
Type: Journal Article
Subjects: Anti-PD-1 antibodies
Cancer
Checkpoint inhibitors
Chemotherapy
Immunotherapy
Melanoma
Appears in Collections:Journal articles

Show full item record

Page view(s)

2
checked on Jun 6, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.